Ipilimumab and Nivolumab
About
Membership operator: AND
Therapies: 2
Therapies
Ipilimumab (tx:ncit:C2654)
Nivolumab (tx:ncit:C68814)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (4) FDA (4) | MSI-H | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| FDA (2) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (2) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| EMA (4) FDA (4) | dMMR | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| EMA (2) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab |